Neko Health and Neuralink reportedly collaborate to screen trial candidates using body-scan data

Two of the most talked-about health-tech companies are apparently joining forces. Neko Health and Neuralink are collaborating on a survey that leverages Neko’s body-scan data to screen potential candidates for Neuralink’s clinical trials, according to a social media announcement. What Neko brings to the table Neko Health has built a business around preventive health monitoring through advanced full-body scans. Each one-hour session uses proprietary sensors to assess skin health, cardiovascular function, and a range of other biological metrics, generating millions of individual data points per patient. The service is priced at $499 in the US market, where the company is actively expanding. Neko raised $700 million in its Series C funding round, which closed on July 15, 2026, specifically to fuel its push into the US. Its first American clinic is scheduled to open in New York City on September 24, 2026. Neuralink’s screening problem Neuralink’s PRIME Study, its flagship clinical trial, targets patients with quadriplegia resulting from spinal cord injuries or amyotrophic lateral sclerosis (ALS). The eligibility criteria are narrow, the medical stakes are enormous, and the consequences...